• The announcement came in a release today from the regulator that said it’s authorizing 23andMe to market a specific test to consumers for Bloom Syndrome, a rare inherited disorder associated with short stature and various cancers that often result in death by the mid-20s.
  • The agency then proceeded to lay out broader plans for reversing its stance on direct-to-consumer tests to screen for genetic carriers of diseases.
  • More important, it’s not yet clear that 23andMe can sell its genetic tests for a wide variety of disease screening all at once.

Share This Article